Balincan USA, Inc.
BCNN · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | -118.22% | -0.17% | 0.00% |
| EV / EBITDA | 0.00 | -0.98 | -127.55 | 0.00 |
| Quality | ||||
| ROIC | 0.00% | 44.37% | -9.64% | 0.00% |
| Gross Margin | 38.52% | 39.00% | 40.93% | 0.00% |
| Cash Conversion Ratio | -0.23 | -1.26 | 0.13 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.98% | – | 1,164.34% | – |
| Free Cash Flow Growth | 0.00% | -2,227.33% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.70 | -6.94 | 0.00 |
| Interest Coverage | -0.52 | -4.62 | 3.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -377.23 | -20.95 | 0.00 |